Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Bi Xiang Zhang"'
Autor:
Qian yun Ge, Jin Chen, Gan xun Li, Xiao long Tan, Jia Song, Deng Ning, Jie Mo, Peng cheng Du, Qiu meng Liu, Hui fang Liang, Ze yang Ding, Xue wu Zhang, Bi xiang Zhang
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 11, Pp n/a-n/a (2021)
Abstract Background Aberrant TAK1 (transforming growth factor β‐activated kinase 1) activity is known to be involved in a variety of malignancies, but the regulatory mechanisms of TAK1 remain poorly understood. GRAMD4 (glucosyltransferase Rab‐li
Externí odkaz:
https://doaj.org/article/53eba7c6cc954f4fae0d49a14cfacd22
Autor:
Chang Zhu, Jing-Yu Liao, Yi-Yang Liu, Ze-Yu Chen, Rui-Zhi Chang, Xiao-Ping Chen, Bi-Xiang Zhang, Jun-Nan Liang
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-25 (2024)
Abstract Liver metastases are commonly detected in the advanced stages of various malignant tumors, representing a significant clinical challenge. Throughout the process of liver metastases formation, immune cells play a pivotal role, particularly in
Externí odkaz:
https://doaj.org/article/2adfb76fc05c48a88dcf18fddf85136c
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-25 (2023)
Abstract Glycolytic reprogramming is one of the most important features of cancer and plays an integral role in the progression of cancer. In cancer cells, changes in glucose metabolism meet the needs of self-proliferation, angiogenesis and lymphangi
Externí odkaz:
https://doaj.org/article/dc3efa7a53384948864b946a2cf80f7e
Autor:
Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Hai‐Bo Mou, Le‐Qun Bao, Hai‐Tao Zhao, Hong Zhao, Xie‐Lin Feng, Bi‐Xiang Zhang, Tao Peng, Yu‐Bao Zhang, Xiang‐Cheng Li, Hong‐Sheng Yu, Yu Cao, Lian‐Xin Liu, Ti Zhang, Wei‐Lin Wang, Jiang‐Hua Ran, Ying‐Bin Liu, Wei Gong, Ming‐Xia Chen, Lian Cao, Yang Luo, Yan Wang, Hui Zhou, Guo‐Huan Yang, Jia Fan, Jian Zhou
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4137-4146 (2023)
Abstract Objective This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Background Pem
Externí odkaz:
https://doaj.org/article/33db6e2caae9409c859c394540b3696a
Autor:
Qiang Wang, Shiyou Li, Chen Xu, Ao Hua, Chong Wang, Yuxuan Xiong, Qingyuan Deng, Xiang Chen, Tian Yang, Jiangling Wan, Ze-yang Ding, Bi-xiang Zhang, Xiangliang Yang, Zifu Li
Publikováno v:
Pharmacological Research, Vol 190, Iss , Pp 106740- (2023)
Cancer stem cells (CSCs) have been blamed as the main culprit of tumor initiation, progression, metastasis, chemoresistance, and recurrence. However, few anti-CSCs agents have achieved clinical success so far. Here we report a novel derivative of lon
Externí odkaz:
https://doaj.org/article/51d8fd1160024e8caa073b5b9746b39f
Publikováno v:
Frontiers in Surgery, Vol 10 (2023)
BackgroundLiver cancer is now the fourth most common cancer in China. The most important factor in decreasing the overall survival is recurrence. Nearly 40%–70% of patients would be detected with intrahepatic or extrahepatic recurrence in 5 years a
Externí odkaz:
https://doaj.org/article/2fe36637217949af925d549c9ac741cb
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
BackgroundIntrahepatic cholangiocarcinoma (ICC) is a highly malignant biliary tumor. Patients with unresectable and advanced ICC have a poor prognosis with current gemcitabine-based chemotherapy. Combination therapy strategies based on immunotherapy
Externí odkaz:
https://doaj.org/article/cb607c645f3547638a3bd21d913d4316
Autor:
Jing-jing Wu, Zhan-guo Zhang, Peng Zhu, Abdoul-aziz Mba'nbo-koumpa, Bi-xiang Zhang, Xiao-ping Chen, Chang Shu, Wan-guang Zhang, Ren-jie Feng, Gan-xun Li
Publikováno v:
Asian Journal of Surgery, Vol 42, Iss 9, Pp 874-882 (2019)
Summary: Background/Objective: Previous studies have proposed several objective means for liver function assessment in hepatocellular carcinoma (HCC) patients; however, their efficiency in predicting survival of HCC rupture is unknown. Our study aims
Externí odkaz:
https://doaj.org/article/f8929d8a4a7a4110a97edb90bd68132e
Autor:
Zhao‐qi Zhang, Jin Chen, Wan‐qiu Huang, Deng Ning, Qiu‐meng Liu, Chao Wang, Long Zhang, Li Ren, Liang Chu, Hui‐fang Liang, Hai‐ning Fan, Bi‐xiang Zhang, Xiao‐ping Chen
Publikováno v:
Molecular Oncology, Vol 13, Iss 4, Pp 792-810 (2019)
Fam134b (JK‐1, RETREG1) was first identified as an oncogene in esophageal squamous cell carcinoma. However, the roles of FAM134B during tumorigenesis of hepatocellular carcinoma (HCC) and in epithelial‐to‐mesenchymal transition (EMT) were previ
Externí odkaz:
https://doaj.org/article/77ec456b105c4a1fb9f2414393c07d82
Autor:
Chen Xiao, Jiayuan Li, Xing Wang, Shiyou Li, Chen Xu, Zhijie Zhang, Ao Hua, Ze-yang Ding, Bi-xiang Zhang, Xiangliang Yang, Zifu Li
Publikováno v:
Journal of Controlled Release. 356:288-305
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86a46ca86f9a3a64f20599aaa81af502
https://doi.org/10.1016/j.jconrel.2023.02.043
https://doi.org/10.1016/j.jconrel.2023.02.043